SCHEMBL4959876

SCHEMBL4959876

CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(=O)OCCCCO[N+](=O)[O-])C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 3/20 0.37
ITGA4 P13612 3/20 0.37
PTGS2 P35354 3/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
THRB P10828 1/20 0.36
ALOX15 P16050 1/20 0.36
NFKB1 P19838 1/20 0.36
THPO P40225 1/20 0.36
RECQL P46063 1/20 0.36
BLM P54132 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 2/20 0.35
NOD1 Q9Y239 2/20 0.33
ITGB3 P05106 1/20 0.33
ITGA2B P08514 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4585907 0.81 MAPT (0.37) PTGS2MAPTKDM4ETHRBALOX15
SCHEMBL6631370 0.80 PTGS2 (0.44) PTGS2MAPTKDM4ETHRBALOX15
SCHEMBL4957168 0.80 PTGS2 (0.44) PTGS2MAPTKDM4ETHRBALOX15
SCHEMBL5133823 0.80 MAPT (0.37) PTGS2MAPTKDM4ETHRBALOX15
SCHEMBL5133824 0.80 MAPT (0.37) PTGS2MAPTKDM4ETHRBALOX15
SCHEMBL13105633 0.76 NOD1 (0.35) PTGS2SMN1; SMN2ALDH1A1NOD1CA12
SCHEMBL21939897 0.76 PTGS2 (0.32) PTGS2PTGS1
SCHEMBL12443668 0.76 MAPT (0.34) ITGB1ITGA4PTGS2MAPTKDM4E
SCHEMBL4587971 0.76 ALDH1A1 (0.36) PTGS2MAPTKDM4ETHRBALOX15
SCHEMBL11773441 0.75 SMN1; SMN2 (0.46) ITGB1ITGA4PTGS2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378387-B2 Method of suppressing immune response by reducing intracellular content of glutathione in macrophages and monocytes AJINOMOTO CO., INC. (JP) 2008-05-27 US disclosed
US-20050239886-A1 Method of suppressing immune response by reducing intracellular content of glutathione in macrophages and monocytes AJINOMOTO CO., INC. (JP) 2005-10-27 US disclosed
US-20010000784-A1 METHOD OF SUPRESSING IMMUNE RESPONSES BY REDUCING INTRACELLULAR CONTENT OF GLUTATHIONE IN MACROPHAGES AND MONOCYTES AJINOMOTO CO. INC. (JP) 2001-05-03 US disclosed
US-6197749-B1 THERAPY FOR CANCER, DIABETES, GASTROINTESTINAL DISEASES, INFLAMMATION, ARTHRITIS AJINOMOTO CO., INC. (JP) 2001-03-06 US disclosed
EP-1004302-A2 Immunomodulator Ajinomoto Co., Ltd. (JP) 2000-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010000784-A1 METHOD OF SUPRESSING IMMUNE RESPONSES BY REDUCING INTRACELLULAR CONTENT OF GLUTATHIONE IN MACROPHAGES AND MONOCYTES GSR, GPX1, CD14 ITGB1 4152/4885ITGA4 4465/4885PTGS2 55/4885
US-20050239886-A1 Method of suppressing immune response by reducing intracellular content of glutathione in macrophages and monocytes GSR, CD14, GPX1 ITGB1 4101/4885ITGA4 4202/4885PTGS2 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.